TO THE EDITOR We read with interest the letter by Chee et al 1 reporting a case of chronic myeloid leukemia (CML) with a fatal myelodysplastic syndrome developing during imatinib mesylate therapy and characterized by the emergence of Philadelphia (Ph)-negative clones harboring a complex karyotype with a 5qÀ. We would like to describe a further patient with very similar features.
The patient, a 34-year-old man, was diagnosed as a Phpositive chronic phase CML in December 1993 (karyotyping results are reported in Table 1 ). He was initially treated with interferon alpha (IFN) and obtained a complete cytogenetic response to treatment in January 1996. As he was intolerant to IFN, he received an intensive chemotherapy (six courses of ROAP: Rubidomycine 60 mg/m 2 , vincristine 2 mg, cytosine arabinoside 100 mg/m 2 , prednisone 300 mg/m 2 ) followed by an autologous transplantation with peripheral blood stem cells in January 1997. The condition for transplantation consisted of busulfan (1260 mg) and melphalan (280 mg). Treatment was then carried on with IFN until December 2000. Throughout this period, karyotypes showed a major or a minor response (Table 1) and reverse transcriptase-polymerase chain reaction (RT-PCR) for the MBCR-ABL transcript showed no residual molecular disease 3 months after the graft, and a strong residual molecular disease at 9, 20 and 41 months. In July 2001, the bone marrow was hypoplastic without features of myelodysplasia, and the karyotype showed 96% Ph-negative mitoses including a minor clone with 5qÀ and complex abnormalities as well as a nonclonal 7qÀ. In August 2001, he received imatinib mesylate (Gleevec 400 mg/day) and his bone marrow became 100% Ph negative without other abnormalities. After 19 months of imatinib mesylate, he developed pancytopenia and his bone marrow was hyperplastic with marked multilineage dysplasia but only 3% myeloblasts. Interestingly, we could note that the megakaryocytes did not have the morphologically characteristic features of the 5qÀ syndrome. All the mitoses were Ph negative, with complex clonal abnormalities, including the same abnormalities as in July 2001. At the present time, Imatinib has been stopped and replaced by low doses of cytosine arabinoside. The pancytopenia persists and the patient is asthenic.
The development of cytogenetic clonal abnormalities in Phnegative clones after therapy of Ph-positive CML with imatinib mesylate is a newly reported phenomenon.
2 The mechanisms of the emergence of these abnormal clones are not clear. Several hypotheses might be suggested. First, imatinib, specifically targeting the Ph-positive clone, may confer a growth advantage to preleukemic silent clones initially present at a low level or secondarily developed in Ph-negative stem cells that might have suffered from chemotherapy. Second, the cytogenetic abnormalities in Ph-negative cells may be a direct consequence of imatinib toxicity and of its action on other tyrosine kinase receptors like c-kit or PDGFRB. Our patient shared some features similar to those reported by Chee et al, who received an allograft conditioned with TBI and cyclophosphamide and was then treated with IFN and cytarabine before imatinib mesylate. Like our patient, he developed complex chromosomal abnormalities with loss of chromosomes 5q and 7q in the Ph-negative clone, going on with pancytopenia and trilineage dysplasia. However, in our patient, the abnormal Ph-negative clone began to appear just before the administration of imatinib, and 4.5 years after intensive chemotherapy and autologous transplantation. The appearance of the cytogenetic abnormalities may be due to this treatment. This might be especially relevant after autografting, where myelodysplasia is more frequently reported.
3 It is also possible that these features were secondary to the previous IFN therapy as few similar cases had been documented in CML patients treated with IFN, and some of these patients had subsequently developed myelodysplasia.
1,2,4 Indeed, patient 1 reported by Fayad et al 4 was treated by IFN for 4 years, achieved complete cytogenetic remission before presenting with a minor Phnegative clone with a 5qÀ, followed by two normal karyotypes and a clonal Ph-negative evolution 6 months later.
Most of the cytogenetic abnormalities described by different authors in the Ph-negative clones after imatinib mesylate or IFN were trisomy 8 and partial or complete loss of chromosome 7.
1,2,4À7 Our case, like the case of Chee et al, presented with related clones and abnormalities evocative of secondary myelodysplasia.
Whereas additional investigations are required for these cases, as suggested by others, the morphologic and cytogenetic follow-up of patients receiving imatinib remain imperative, especially if they have previously received leukemogenic therapy. 
